
|Articles|November 22, 2013
BBK Worldwide Builds on Tablet Function in Latest Version of Study eBinder
Author(s)Lisa Henderson
BBK Worldwide announced the latest version its Study eBinder
Advertisement
BBK Worldwide announced the latest version its Study eBinder, which addresses more customization for its tablet that study teams use. Version 3.0 provides more than 300 real-time reports and a protected instant messaging system for sponsors to connect directly with physician investigators and site staff in its proprietary patient recruitment portal, TrialCentralNet (TCN®). The new version also is fully customizable for the sponsor's brand and content.
You can read the full release
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Fortrea to Acquire Worldwide Clinical Trials' Early Phase Services Division in $45 Million Deal
2
Agentic AI and the Administrative Backbone of Clinical Trials: Why the Operating Model Has to Change First
3
FDA Reaffirms GCP Standards Amid Growing Concerns Over Foreign Clinical Trial Data
4
Why Time Savings Is the Largest Driver of RBQM's Financial Value
5



